Cosmos Health Inc., (NASDAQ: COSM), is an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications and medical devices through an extensive, established EU and UK distribution network. The Company identifies, acquires, develops and...
On March 14 2022, The Nektar Therapeutics (NASDAQ: NKTR) announced that a review by an independent Data Monitoring Committee (DMC) evaluating the safety and efficacy of bempegaldesleukin in combination with Opdivo (nivolumab), revealed that the study has failed to meet the primary endpoints of progression-free...
Allakos, Inc. (NASDAQ: ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial. The studies were evaluating the Company’s...
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biotechnology company, developing leading-edge orally delivered large molecule therapeutics, announced pivotal 6-month bone mineral density (BMD) results from the Phase 2 clinical trial of EB613, intended for the treatment of osteoporosis. EB613, the Company’s lead candidate for the...
Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) was one of our stock picks this week based on its promising pipeline and an impending FDA approval for FOTIVDA® (tivozanib). The Company has scored a big win with its approval, which not only validates its unique approach but also...
While Industries across the globe are grappling with the pandemic and its impact on their operations, Technology Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs, be it healthcare, contactless payments or big data analysis. Artificial Intelligence is witnessing...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is in the spotlight after receiving a “Buy” rating along with a $30 price target from Ram Selvaraju an analyst at H.C Wainwright, implying a nearly 275% upside from its current levels. We take a look at reasons for the...
While Industries across the globe are grappling with the pandemic and its impact on their operations, Biotech Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs. We take a look at some Biotech’s that are impervious to the scare...
Surgalign Holdings (NASDAQ: SRGA), a pure-play spine company focused on leveraging digital technology to improve spine surgery, announced the acquisition of HOLOSurgical Inc and its revolutionary Augmented Reality and Artificial Intelligence based digital surgery platform named ARAI. The technology has the potential to be the...
Agenus Inc (NASDAQ: AGEN), a clinical-stage immune-oncology company developing innovative therapies for treatment of cancer, announced the grant of a Fast Track designation for investigation of balstilimab [PD-1] in combination with zalifrelimab [CTLA-4] for the treatment of patients with relapsed or refractory metastatic cervical cancer. [caption...
